Ceftazidime-avibactam: An evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

Core Evidence

Volumn 9, Issue , 2014, Pages 13-25

  Lagacé Wiens, Philippe ^a,b   Walkty, Andrew ^a,b   Karlowsky, James A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Clinical trials; Microbiology; NXL 104; Pharmacokinetics; Review; lactamase

Indexed keywords

AVIBACTAM; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; METRONIDAZOLE;

ABDOMINAL INFECTION; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IN VITRO STUDY; MENINGITIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

EID: 84894441748     PISSN: 1555175X     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S40698     Document Type: Review

References (69)

1. Andes DE, Craig WA. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:323-337.
2. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70:313-333.
3. Bush K. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol. 2010;13:558-564.
4. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006;14:413-420.
5. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64 Suppl 1:i29-i36.
6. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis. 2009;63:217-222.
7. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ. Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America - SMART 2002-2009. J Chemother. 2011;23:266-272.
8. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis. 2011;70:507-511.
9. Aszodi J, Fromentin C, Lampilas M, et al; Aventis Pharma SA, assignee. Heterocyclic compounds which are active as inhibitors of β-lactamases, 2003. International Patent number PCT/FR2003/000243. Jan 27, 2003.
10. Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-beta- lactam beta-lactamase inhibitors. Curr Opin Microbiol. 2011;14: 550-555.
11. AztraZeneca. Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections). Available from: http://clinicaltrials.gov/ct2/show/NCT01595438. NLM Identifier: NCT01595438. Accessed November 26, 2013.
12. AztraZeneca. Compare Ceftazidime-Avibactam and Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections). Available from: http://clinicaltrials.gov/ct2/ show/NCT01599806. NLM Identifier: NCT01599806. Accessed November 26, 2013.
13. AstraZeneca. Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections. Available from http://clinicaltrials.gov/ct2/show/NCT01499290. NLM Identifier: NCT01499290. Accessed November 26, 2013.
14. AstraZeneca. A Study Comparing Ceftazidime-Avibactam+ Metronidazole Versus Meropenem in Adults With Complicated Intraabdominal Infections. Available from: http://clinicaltrials.gov/ct2/show/NCT01500239. NLM Identifier: NCT01500239. Accessed November 26, 2013.
15. Beale JM Jr. Antibacterial antibiotics. In: Beale JM Jr, Block J, editors. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. 12th ed. Baltimore, MD: Lippincott Williams and Wilkins; 2011:258-329.
16. Dunn GL. Ceftizoxime and other third-generation cephalosporins: structure-activity relationships. J Antimicrob Chemother. 1982;10 Suppl C: 1-10.
17. Caprile KA. The cephalosporin antimicrobial agents: a comprehensive review. J Vet Pharmacol Ther. 1988;11:1-32.
18. Neu HC. beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis. 1986; 8 Suppl 3:S237-S259.
19. Neu HC. Beta-lactamase stability of cefoxitin in comparison with other beta-lactam compounds. Diagn Microbiol Infect Dis. 1983;1:313-316.
20. Miossec C, Merdjan H, Hodgson J. Safety and toxicokinetics of NXL104, a broad spectrum β-lactamase inhibitor, in the rat [abstract no F-1461]. Paper presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
21. Miossec C. Progress of a novel non-beta-lactam beta-lactamase inhibitor towards the clinic. Paper presented at: The Challenge of Antimicrobial Drug Development - Integrating Chemistry and Biology; March 21-22, 2007; San Diego, CA.
22. Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39:86-89.
23. Stachyra T, Levasseur P, Péchereau MC, et al. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009;64:326-329.
24. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68:1183-1192.
25. Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime- avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:6137-6146.
26. Levasseur P, Girard AM, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56:1606-1608.
27. Citron DM, Tyrrell KL, Merriam V, Goldstein EJ. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 2011;55:3616-3620.
28. Curcio D. Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. Expert Rev Anti Infect Ther. 2011;9:173-176.
29. Walkty A, DeCorby M, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011;55:2992-2994.
30. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010;65:2376-2381.
31. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from US. Medical Centers in 2010-2011. Antimicrob Agents Chemother. 2013;57: 1982-1988.
32. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73: 159-177.
33. Lagacé-Wiens PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother. 2011;55:2434-2437.
34. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009;53:3599-3601.
35. Karlowsky JA, Adam HJ, Baxter MR, et al. In vitro activity of ceftaroline-avibactam against Gram-negative and Gram-positive pathogens isolated from patients in Canadian hospitals in 2010-2012: results from the CANWARD Surveillance Study. Antimicrob Agents Chemother. 2013;57:5600-5611.
36. Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane/ tazobactam versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2007-2012. Antimicrob Agents Chemother. 2013.
37. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998; 27 Suppl 1:S93-S99.
38. Dubreuil LJ, Mahieux S, Neut C, Miossec C, Pace J. Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole. Int J Antimicrob Agents. 2012;39: 500-504.
39. Hayes MV, Orr DC. Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983;12:119-126.
40. Stachyra T, Péchereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54: 5132-5138.
41. Bush K. The ABCD's of beta-lactamase nomenclature. J Infect Chemother. 2013;19:549-559.
42. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440-458, Table of contents.
43. Cantón R, Morosini MI, de la Maza OM, de la Pedrosa EG. IRT and CMT beta-lactamases and inhibitor resistance. Clin Microbiol Infect. 2008;14 Suppl 1:53-62.
44. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161-182, Table of Contents.
45. Livermore DM. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 2008;14 Suppl 1:3-10.
46. Ehmann DE, Jahic H, Ross PL, et al. Kinetics of avibactam inhibition against class A, C, and D beta-lactamases. J Biol Chem. 2013;288:27960-27971.
47. Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109:11663-11668.
48. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase- producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65:1428-1432.
49. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012;67:1354-1358.
50. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300:371-379.
51. Richards DM, Brogden RN. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985;29:105-161.
52. Merdjan H, Tarral A, Girard AM, et al. Safety, single dose pharmacokinetics, and pharmacodynamics of β-lactamase inhibitor NXL104 in healthy young male adults [abstract A-809]. Paper presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL.
53. Tarral A, Lipka J, Gyaw S, et al. Effect of age and gender on the pharmacokinetics (PK) and safety of NXL104 in health subjects (protocol NXL104/1004) [abstract A1-007]. Paper presented at: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, 2009; San Francisco, CA.
54. Edeki T, Armstrong J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers [abstract A-1019]. 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.
55. Felices M, Gualano V, Tarral A, Sable C, Merdjan H. Combined population pharmacokinetic analysis of four phase 1studies with NXL104 [abstract P1599]. 20th European Congress of Clinical Microbiology and Infectious Diseases; April 10-13, 2010; Vienna, Austria.
56. Li J, Knebel W, Riggs M, Zou D, Nichols W, Das S. Population pharmacokinetic modeling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-abdominal infection (cIAI) [abstract A-634]. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.
57. Nicolau DP, Siew L, Armstrong J, Edeki T, Bouw R. Concentration of avibactam (AVI) and ceftazidime (CAZ) in plasma and epithelial lining fluid (ELF) in healthy volunteers [abstract A-1027]. 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.
58. Huband MD, Otterson LG, Andrews B, Nichols WW. Effect of pulmonary surfactant on the in vitro antibacterial activity of ceftazidime-avibactam [abstract E-1170]. 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.
59. Merdjan H, Tarral A, Haazen W, Evene E, Robertson M, Sable C. Pharmacokinetics and tolerability of NXL104 in normal subjects and patients with varying degrees of renal insufficiency [abstract P1598]. 20th European Congress of Clinical Microbiology and Infectious Diseases; April 10-13, 2010; Vienna, Austria.
60. Levasseur P, Girard A, Coleman K. Optimal administration of ceftazidime (CAZ) plus avibactam (NXL104) for in vitro bacterial growth suppression of Enterobacteriaceae [abstract A-1688]. 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-17, 2011; Chicago, IL.
61. Noel AR, Tomaselli SG, Nicholls DL, Bowker KE, Williams G, MacGowan AP. The pharmacodynamics of avibactam (NXL104) in combination with either ceftaroline or ceftazidime against β-lactamase producing Enterobacteriaceae [abstract A-631]. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.
62. Bowker KE, Noel AR, Macgowan AP. Pharmacodynamics of NXL104 plus either ceftaroline or ceftazidime against an AmpC producing Enterobacter spp. [abstract A2-556]. 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
63. Merdjan H, Girard AM, Miossec C, Robertson M, Levasseur, P. Pharmacokinetics (PK) and efficacy of ceftazidime (CAZ)/NXL104 combination in a murine pneumonia model caused by an AmpC-producing Klebsiella pneumoniae [abstract A1-006]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA.
64. Levasseur P, Girard AM, Lavallade L, et al. Efficacy of ceftazidime/ NXL104 combination in murine septicemia caused by extended-spectrum β-lactamases and AmpC-producing Enterobacteriaceae sp. [abstract P1564]. 20th European Congress of Clinical Microbiology and Infectious Diseases; April 10-13, 2010; Vienna, Austria.
65. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:82-85.
66. Cottagnoud P, Merdjan H, Acosta F, et al. Pharmacokinetics of the new β-lactamase inhibitor NXL104 in an experimental rabbit meningitis model: restoration of the bacteriological efficacy of ceftazidime (CAZ) against a class C producing K. pneumoniae [abstract F1-321]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL.
67. Borgonovi M, Miossec C, Lowther J. The efficacy of ceftazidime combined with NXL104, a novel β-lactamase inhibitor, in a mouse model of kidney infections induced by β-lactamase producing Enterobacteriaceae [abstract P794]. 17th European Congress of Clinical Microbiology and Infectious Diseases; March 31-April 3, 2007; Munich, Germany.
68. Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921-1931.
69. Edeki T, Das S, Armstrong J, Mathews D. Effect of a supratherapeutic dose of ceftazidime on the QTc interval in a thorough QTc study [abstract P1417]. 22nd European Congress of Clinical Microbiology and Infectious Diseases; March 31-April 3, 2012; London, UK.